Evidence map›Paper›PMID 36912768›Full record

ArticleMolecular oncology2023

Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers.

Lucas Blasquez, Haniaa Bouzinba-Segard, Sandrine Bourdoulous, Camille Faure

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lucas BlasquezUniversité Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.
Haniaa Bouzinba-SegardUniversité Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.
Sandrine BourdoulousUniversité Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.
Camille FaureUniversité Paris Cité, CNRS, INSERM, Institut Cochin, Paris, France.ORCID 0000-0003-1776-2848
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor receptor 2 (ErbB2/HER2) is a tyrosine kinase receptor that is overexpressed in 25% of primary human breast cancers, as well as in multiple other cancers. HER2-targeted therapies improved progression-free and overall survival in patients with HER2

Indexed as

Antineoplastic AgentsBreast NeoplasmsAzolesCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibOrganoselenium CompoundsProtein Kinase InhibitorsQuinazolinesAntineoplastic AgentsAzolesebselen oxideErb-b2 Receptor Tyrosine KinasesLapatinibOrganoselenium CompoundsProtein Kinase InhibitorsQuinazolinesadditive effectsbreast cancerHER2 tyrosine kinase receptorresistancesmall molecule inhibitortargeted therapy

Identifiers

PMID36912768
PMCPMC10552892
OpenAlexW4324017926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.